---
title: "Tuoxin Pharmaceutical: The application for the listing of the raw material drug cytidine diphosphocholine has been approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/247471977.md"
description: "Tuoxin Pharmaceutical's wholly-owned subsidiary, Xinxiang Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of its raw material drug, cytidine diphosphate choline. Cytidine diphosphate choline is a commonly used neuroprotective agent, primarily used to improve brain function and promote nerve repair, suitable for patients with brain injuries, cerebrovascular diseases, and neurodegenerative diseases"
datetime: "2025-07-07T10:09:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/247471977.md)
  - [en](https://longbridge.com/en/news/247471977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/247471977.md)
generator: "portal-rs"
---

# Tuoxin Pharmaceutical: The application for the listing of the raw material drug cytidine diphosphocholine has been approved

According to the Zhitong Finance APP, Tuoxin Pharmaceutical (301089.SZ) announced that its wholly-owned subsidiary Xinxiang Pharmaceutical Co., Ltd. (referred to as "Xinxiang Pharmaceutical") has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration, which has been publicly announced on the official website of the Drug Evaluation Center of the National Medical Products Administration.

The announcement shows that phosphatidylcholine, as a commonly used neuroprotective agent and brain metabolism activator in clinical practice, has its core pharmacological effect in improving brain function and promoting nerve repair. Its clinical application scope covers patient groups with brain injuries, cerebrovascular diseases, and neurodegenerative diseases

### Related Stocks

- [301089.CN](https://longbridge.com/en/quote/301089.CN.md)

## Related News & Research

- [Haisco Enters Into Exclusive License Agreement With New US Venture Founded By Population Health Partners And ARCH Venture Partners](https://longbridge.com/en/news/296910145.md)
- [SP Group corrects disclosure, names Schur Finance as buyer of 31,500 shares at DKK 485](https://longbridge.com/en/news/296803384.md)
- [BMS Holdings Q4 FY2026 PAT Rises 106.5% QoQ to RM5.04 Million](https://longbridge.com/en/news/296892849.md)
- [MediaTek’s rumored Dimensity 9600 Pro appears in benchmark leak](https://longbridge.com/en/news/296869710.md)
- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**